Finance

Lists
Why is KLRS up 12,71%?
Dive Deeper
KLRS:NASDAQ
Kalaris Therapeutics Inc
USD 2,66
+12,71%
(+0,30) 1D
6 Nov., 11:20:50 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KLRS...
Open
USD 2,36
High
USD 2,66
Low
USD 2,34
Mkt. cap
63,32 m
Avg. vol.
77,31 k
Volume
102,66 k
52-wk high
USD 11,88
52-wk low
USD 1,78
EPS
-USD 2,09
Beta
0,47
Shares outstanding
23,80 m
No. of employees
20
Open
USD 2,36
High
USD 2,66
Low
USD 2,34
Mkt. cap
63,32 m
Avg. vol.
77,31 k
Volume
102,66 k
52-wk high
USD 11,88
52-wk low
USD 1,78
EPS
-USD 2,09
Beta
0,47
Shares outstanding
23,80 m
No. of employees
20
News stories
From web sources and news partners
Marin Independent Journal
Marin Independent Journal
·
25 minute gelede
Nasdaq stumbles are worrisome for California economy
qz.com
qz.com
·
39 minute gelede
Magnificent Seven stocks and their share of the S&P 500
CNBC
CNBC
·
1 uur gelede
Opening Bell: November 6, 2026
Seeking Alpha
Seeking Alpha
·
41 minute gelede
The Path Forward After This Mini-Meltdown
About Kalaris Therapeutics Inc
CEO-
Employees20
Founded2019
HeadquartersBerkeley Heights, New Jersey, Verenigde State van Amerika
SectorHealth Care
Industry-
Websitekalaristx.com
Analyst ratings
Based on 3 analysts giving stock ratings to KLRS in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for KLRS in the last 3 months.
Highest
Current USD 2,66
USD 17,00 (+539,10%)
Average
USD 15,50 (+482,71%)
Lowest
USD 14,00 (+426,32%)
Analyst
Recommendation
Action
Price target
Projected
Date
Judah Frommer
Morgan Stanley
Buy
Reiterated
USD 14,00
+426,3%
08/12/2026
Yun Zhong
Wedbush
Buy
Reiterated
USD 17,00
+539,1%
08/11/2026
Lachlan Hanbury Brown
William Blair
Buy
Maintained
-
-
08/11/2026
Tara Bancroft
TD Cowen
Buy
Initiated
-
-
06/15/2026
Jonathan Wolleben
Citizens JMP
Buy
Maintained
USD 25,00
+839,8%
05/13/2026
Biren Amin
Piper Sandler
Hold
Maintained
USD 7,00
+163,2%
03/30/2026
Daniil Gataulin
Chardan Capital
Buy
Initiated
USD 19,00
+614,3%
12/23/2025
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
9,13 m
7,16 m
7,57 m
9,02 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3,62 m
3,64 m
4,26 m
3,37 m
Operating expense
12,74 m
10,80 m
11,83 m
12,39 m
Total operating expenses
12,74 m
10,80 m
11,83 m
12,39 m
Operating income
-12,74 m
-10,80 m
-11,83 m
-12,39 m
Other non operating income
847,00 k
803,00 k
977,00 k
871,00 k
EBT including unusual items
-11,89 m
-10,00 m
-10,86 m
-11,52 m
EBT excluding unusual items
-11,89 m
-10,00 m
-10,86 m
-11,52 m
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-11,89 m
-10,00 m
-10,86 m
-11,52 m
Net profit margin
-
-
-
-
Earnings per share
-0,64
-0,44
-0,46
-0,48
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-12,74 m
-10,79 m
-11,82 m
-12,38 m
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme